Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: Results from the 'TRIPOD' trials

Leprosy Review

Volumn 74, Issue 4, 2003, Pages 319-327

  Richardus, Jan H ^a   Withington, Stephen G ^b   Anderson, Alison M ^c   Croft, Richard P ^d   Nicholls, Peter G ^e   Van Brakel, Wim H ^f   Smith, W Cairns S ^e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Danish Bangladesh Leprosy Mission   (Bangladesh)

^c International Nepal Fellowship   (Nepal)

^d Polwarth Building ^*  (United Kingdom)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f ROYAL TROPICAL INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PLACEBO; PREDNISOLONE;

ACNE; ADOLESCENT; ADULT; ARTICLE; BANGLADESH; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA ULCER; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISABILITY; DOUBLE BLIND PROCEDURE; GLAUCOMA; HUMAN; HYPERTENSION; INFECTION; LEPROSY; MAJOR CLINICAL STUDY; MOON FACE; MULTICENTER STUDY; MYCOSIS; NEPAL; NERVE FUNCTION IMPAIRMENT; NEUROPATHY; PEPTIC ULCER; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; STOMACH PAIN; TREATMENT OUTCOME; TUBERCULOSIS;

ADOLESCENT; ADULT; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEPROSY; MALE; MIDDLE AGED; NEPAL; ODDS RATIO; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDNISOLONE; PRIMARY PREVENTION; PROBABILITY; RISK ASSESSMENT; SENSATION DISORDERS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0346787557     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Rose P, Waters MF. Reversal reactions in leprosy and their management. Lepr Rev, 1991; 62: 113-121.
2. Anonymous. Guide to eliminate leprosy as a public health problem. WHO, Geneva, 2000, pp. 32-33.
3. Richardus JH, Smith WC. The risk of standardized regimens of corticosteroids for the treatment of leprosy reactions in the field [letter]. Lepr Rev, 1995; 66: 328-329.
4. Smith WCS, Anderson AM, Withington SG et al. TRIPOD 1-a randomized placebo controlled trial of steroid prophylaxis for the prevention of nerve function impairment in leprosy. Unpublished data.
5. Van Brakel WH, Anderson AM, Withington SG et al. Treatment of mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2). Lepr Rev, 2003; 74: 000-000.
6. Richardus JH, Withington SG, Anderson AM et al. Treatment with corticosteroids of long-standing nerve function impairment in leprosy: a randomized controlled trial (TRIPOD 3). Lepr Rev, 2003; 74: 000-000.
7. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Int Med, 1994; 236: 619-632.
8. The ILEP Action Group on Teaching and Learning Materials. How to recognise and manage leprosy reactions. ILEP, London, 2002.
9. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Int Med, 1999; 159: 941-955.
10. Tam LS, Li EK, Wong SM, Szeto CC. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol, 2002; 31: 269-300.
11. Ng JS, Wong W, Law RW et al. Ocular complications of paediatric patients with nephrotic syndrome. Clin Exp Ophthalmol, 2001; 29: 239-243.